nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2A6—stomach cancer	0.303	1	CbGaD
Buprenorphine—UGT1A9—Irinotecan—stomach cancer	0.0657	0.143	CbGbCtD
Buprenorphine—ABCB1—Mitomycin—stomach cancer	0.0415	0.0906	CbGbCtD
Buprenorphine—CYP2A6—Fluorouracil—stomach cancer	0.0306	0.0669	CbGbCtD
Buprenorphine—ABCG2—Irinotecan—stomach cancer	0.0295	0.0645	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—stomach cancer	0.0283	0.0619	CbGbCtD
Buprenorphine—CYP3A7—Irinotecan—stomach cancer	0.0218	0.0476	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Irinotecan—stomach cancer	0.0218	0.0476	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—stomach cancer	0.0216	0.0473	CbGbCtD
Buprenorphine—CYP2C9—Capecitabine—stomach cancer	0.0178	0.0388	CbGbCtD
Buprenorphine—CYP3A5—Irinotecan—stomach cancer	0.0164	0.0357	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—stomach cancer	0.0161	0.0352	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—stomach cancer	0.016	0.0349	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—stomach cancer	0.016	0.0349	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—stomach cancer	0.0156	0.0341	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—stomach cancer	0.0151	0.033	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—stomach cancer	0.012	0.0262	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—stomach cancer	0.0117	0.0255	CbGbCtD
Buprenorphine—ABCB1—Irinotecan—stomach cancer	0.0107	0.0233	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—stomach cancer	0.0105	0.023	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—stomach cancer	0.00781	0.017	CbGbCtD
Buprenorphine—CYP3A4—Irinotecan—stomach cancer	0.00638	0.0139	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—stomach cancer	0.00582	0.0127	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—stomach cancer	0.00564	0.0123	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—stomach cancer	0.00548	0.012	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—stomach cancer	0.00468	0.0102	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—stomach cancer	0.00349	0.00761	CbGbCtD
Buprenorphine—OPRL1—hematopoietic system—stomach cancer	0.00224	0.0889	CbGeAlD
Buprenorphine—OPRL1—lymphoid tissue—stomach cancer	0.00158	0.0626	CbGeAlD
Buprenorphine—OPRL1—endocrine gland—stomach cancer	0.00129	0.0511	CbGeAlD
Buprenorphine—UGT1A9—digestive system—stomach cancer	0.00102	0.0403	CbGeAlD
Buprenorphine—OPRL1—lymph node—stomach cancer	0.000891	0.0353	CbGeAlD
Buprenorphine—CYP2C18—digestive system—stomach cancer	0.000889	0.0352	CbGeAlD
Buprenorphine—UGT1A9—endocrine gland—stomach cancer	0.00084	0.0333	CbGeAlD
Buprenorphine—OPRM1—hematopoietic system—stomach cancer	0.000788	0.0312	CbGeAlD
Buprenorphine—UGT1A9—liver—stomach cancer	0.000757	0.03	CbGeAlD
Buprenorphine—CYP2C18—endocrine gland—stomach cancer	0.000734	0.0291	CbGeAlD
Buprenorphine—CYP3A7—endocrine gland—stomach cancer	0.000698	0.0277	CbGeAlD
Buprenorphine—CYP2C18—liver—stomach cancer	0.000662	0.0262	CbGeAlD
Buprenorphine—CYP3A7—liver—stomach cancer	0.00063	0.0249	CbGeAlD
Buprenorphine—CYP2C19—hematopoietic system—stomach cancer	0.000543	0.0215	CbGeAlD
Buprenorphine—CYP3A7-CYP3A51P—liver—stomach cancer	0.000535	0.0212	CbGeAlD
Buprenorphine—CYP2C8—hematopoietic system—stomach cancer	0.000474	0.0188	CbGeAlD
Buprenorphine—OPRM1—endocrine gland—stomach cancer	0.000453	0.0179	CbGeAlD
Buprenorphine—CYP1A2—hematopoietic system—stomach cancer	0.000444	0.0176	CbGeAlD
Buprenorphine—CYP2A6—liver—stomach cancer	0.000437	0.0173	CbGeAlD
Buprenorphine—CYP3A5—hematopoietic system—stomach cancer	0.000428	0.0169	CbGeAlD
Buprenorphine—ABCB1—blood vessel—stomach cancer	0.000427	0.0169	CbGeAlD
Buprenorphine—CYP2C9—hematopoietic system—stomach cancer	0.000421	0.0167	CbGeAlD
Buprenorphine—CYP2C19—digestive system—stomach cancer	0.000378	0.015	CbGeAlD
Buprenorphine—CYP3A5—pancreas—stomach cancer	0.000348	0.0138	CbGeAlD
Buprenorphine—CYP3A4—hematopoietic system—stomach cancer	0.000321	0.0127	CbGeAlD
Buprenorphine—CYP2D6—hematopoietic system—stomach cancer	0.000316	0.0125	CbGeAlD
Buprenorphine—CYP2C19—endocrine gland—stomach cancer	0.000312	0.0124	CbGeAlD
Buprenorphine—CYP1A2—digestive system—stomach cancer	0.000308	0.0122	CbGeAlD
Buprenorphine—CYP3A5—digestive system—stomach cancer	0.000298	0.0118	CbGeAlD
Buprenorphine—ABCG2—bone marrow—stomach cancer	0.000295	0.0117	CbGeAlD
Buprenorphine—CYP2C9—digestive system—stomach cancer	0.000293	0.0116	CbGeAlD
Buprenorphine—CYP2C19—liver—stomach cancer	0.000281	0.0111	CbGeAlD
Buprenorphine—CYP2C8—endocrine gland—stomach cancer	0.000272	0.0108	CbGeAlD
Buprenorphine—CYP1A2—endocrine gland—stomach cancer	0.000255	0.0101	CbGeAlD
Buprenorphine—CYP3A5—endocrine gland—stomach cancer	0.000246	0.00974	CbGeAlD
Buprenorphine—CYP2C8—liver—stomach cancer	0.000246	0.00973	CbGeAlD
Buprenorphine—CYP2C9—endocrine gland—stomach cancer	0.000242	0.00958	CbGeAlD
Buprenorphine—ABCG2—liver—stomach cancer	0.000239	0.00946	CbGeAlD
Buprenorphine—CYP1A2—liver—stomach cancer	0.00023	0.0091	CbGeAlD
Buprenorphine—ABCB1—hematopoietic system—stomach cancer	0.000227	0.009	CbGeAlD
Buprenorphine—CYP3A4—digestive system—stomach cancer	0.000223	0.00884	CbGeAlD
Buprenorphine—CYP3A5—liver—stomach cancer	0.000222	0.00878	CbGeAlD
Buprenorphine—CYP2D6—digestive system—stomach cancer	0.00022	0.0087	CbGeAlD
Buprenorphine—CYP2C9—liver—stomach cancer	0.000218	0.00864	CbGeAlD
Buprenorphine—ABCB1—epithelium—stomach cancer	0.000208	0.00823	CbGeAlD
Buprenorphine—ABCB1—pancreas—stomach cancer	0.000185	0.00733	CbGeAlD
Buprenorphine—CYP3A4—endocrine gland—stomach cancer	0.000184	0.00731	CbGeAlD
Buprenorphine—ABCG2—lymph node—stomach cancer	0.000183	0.00725	CbGeAlD
Buprenorphine—CYP2D6—endocrine gland—stomach cancer	0.000182	0.00719	CbGeAlD
Buprenorphine—CYP3A4—liver—stomach cancer	0.000166	0.00659	CbGeAlD
Buprenorphine—CYP2D6—liver—stomach cancer	0.000164	0.00648	CbGeAlD
Buprenorphine—ABCB1—lymphoid tissue—stomach cancer	0.00016	0.00634	CbGeAlD
Buprenorphine—ABCB1—digestive system—stomach cancer	0.000158	0.00626	CbGeAlD
Buprenorphine—ABCB1—bone marrow—stomach cancer	0.000146	0.00577	CbGeAlD
Buprenorphine—ABCB1—endocrine gland—stomach cancer	0.000131	0.00517	CbGeAlD
Buprenorphine—ABCB1—liver—stomach cancer	0.000118	0.00466	CbGeAlD
Buprenorphine—Tinnitus—Epirubicin—stomach cancer	9.37e-05	0.000675	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—stomach cancer	9.35e-05	0.000674	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—stomach cancer	9.35e-05	0.000674	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Capecitabine—stomach cancer	9.34e-05	0.000673	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—stomach cancer	9.33e-05	0.000672	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—stomach cancer	9.33e-05	0.000672	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—stomach cancer	9.32e-05	0.000672	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—stomach cancer	9.32e-05	0.000672	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—stomach cancer	9.32e-05	0.000672	CcSEcCtD
Buprenorphine—Insomnia—Capecitabine—stomach cancer	9.27e-05	0.000668	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—stomach cancer	9.25e-05	0.000667	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—stomach cancer	9.25e-05	0.000666	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—stomach cancer	9.24e-05	0.000666	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—stomach cancer	9.23e-05	0.000665	CcSEcCtD
Buprenorphine—Paraesthesia—Capecitabine—stomach cancer	9.2e-05	0.000663	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—stomach cancer	9.2e-05	0.000663	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—stomach cancer	9.19e-05	0.000662	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—stomach cancer	9.18e-05	0.000662	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—stomach cancer	9.16e-05	0.00066	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—stomach cancer	9.15e-05	0.00066	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—stomach cancer	9.14e-05	0.000659	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—stomach cancer	9.14e-05	0.000659	CcSEcCtD
Buprenorphine—Dyspnoea—Capecitabine—stomach cancer	9.14e-05	0.000659	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—stomach cancer	9.13e-05	0.000658	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—stomach cancer	9.12e-05	0.000657	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—stomach cancer	9.11e-05	0.000657	CcSEcCtD
Buprenorphine—Nausea—Irinotecan—stomach cancer	9.1e-05	0.000656	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—stomach cancer	9.08e-05	0.000654	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—stomach cancer	9.06e-05	0.000653	CcSEcCtD
Buprenorphine—Pain—Docetaxel—stomach cancer	9.05e-05	0.000652	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—stomach cancer	9.05e-05	0.000652	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—stomach cancer	9.04e-05	0.000652	CcSEcCtD
Buprenorphine—ABCB1—lymph node—stomach cancer	9.03e-05	0.00358	CbGeAlD
Buprenorphine—Dyspepsia—Capecitabine—stomach cancer	9.02e-05	0.00065	CcSEcCtD
Buprenorphine—Chills—Epirubicin—stomach cancer	9.02e-05	0.00065	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—stomach cancer	8.96e-05	0.000646	CcSEcCtD
Buprenorphine—Decreased appetite—Capecitabine—stomach cancer	8.91e-05	0.000642	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Capecitabine—stomach cancer	8.85e-05	0.000638	CcSEcCtD
Buprenorphine—Fatigue—Capecitabine—stomach cancer	8.84e-05	0.000637	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—stomach cancer	8.81e-05	0.000635	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—stomach cancer	8.8e-05	0.000635	CcSEcCtD
Buprenorphine—Constipation—Capecitabine—stomach cancer	8.76e-05	0.000632	CcSEcCtD
Buprenorphine—Pain—Capecitabine—stomach cancer	8.76e-05	0.000632	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—stomach cancer	8.75e-05	0.000631	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—stomach cancer	8.75e-05	0.000631	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—stomach cancer	8.72e-05	0.000629	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—stomach cancer	8.71e-05	0.000628	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—stomach cancer	8.69e-05	0.000626	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—stomach cancer	8.67e-05	0.000625	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—stomach cancer	8.67e-05	0.000625	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—stomach cancer	8.66e-05	0.000624	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—stomach cancer	8.63e-05	0.000622	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—stomach cancer	8.63e-05	0.000622	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—stomach cancer	8.62e-05	0.000621	CcSEcCtD
Buprenorphine—Tension—Epirubicin—stomach cancer	8.58e-05	0.000619	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—stomach cancer	8.57e-05	0.000617	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—stomach cancer	8.5e-05	0.000612	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—stomach cancer	8.46e-05	0.00061	CcSEcCtD
Buprenorphine—Feeling abnormal—Capecitabine—stomach cancer	8.44e-05	0.000609	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—stomach cancer	8.44e-05	0.000608	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—stomach cancer	8.43e-05	0.000608	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—stomach cancer	8.41e-05	0.000606	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—stomach cancer	8.4e-05	0.000605	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—stomach cancer	8.4e-05	0.000605	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Capecitabine—stomach cancer	8.38e-05	0.000604	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—stomach cancer	8.38e-05	0.000604	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—stomach cancer	8.37e-05	0.000603	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—stomach cancer	8.37e-05	0.000603	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—stomach cancer	8.34e-05	0.000601	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—stomach cancer	8.24e-05	0.000594	CcSEcCtD
Buprenorphine—Cough—Methotrexate—stomach cancer	8.16e-05	0.000588	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—stomach cancer	8.15e-05	0.000587	CcSEcCtD
Buprenorphine—Urticaria—Capecitabine—stomach cancer	8.14e-05	0.000587	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—stomach cancer	8.12e-05	0.000585	CcSEcCtD
Buprenorphine—Abdominal pain—Capecitabine—stomach cancer	8.1e-05	0.000584	CcSEcCtD
Buprenorphine—Body temperature increased—Capecitabine—stomach cancer	8.1e-05	0.000584	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—stomach cancer	8.1e-05	0.000584	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—stomach cancer	8.09e-05	0.000583	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—stomach cancer	8.09e-05	0.000583	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—stomach cancer	8.04e-05	0.000579	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—stomach cancer	7.98e-05	0.000575	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—stomach cancer	7.96e-05	0.000574	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—stomach cancer	7.96e-05	0.000574	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—stomach cancer	7.96e-05	0.000574	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—stomach cancer	7.94e-05	0.000572	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—stomach cancer	7.93e-05	0.000571	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	7.9e-05	0.00057	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—stomach cancer	7.89e-05	0.000569	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—stomach cancer	7.86e-05	0.000567	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—stomach cancer	7.86e-05	0.000567	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—stomach cancer	7.86e-05	0.000566	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—stomach cancer	7.84e-05	0.000565	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—stomach cancer	7.83e-05	0.000564	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—stomach cancer	7.8e-05	0.000562	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—stomach cancer	7.78e-05	0.000561	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—stomach cancer	7.73e-05	0.000557	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—stomach cancer	7.69e-05	0.000554	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—stomach cancer	7.69e-05	0.000554	CcSEcCtD
Buprenorphine—Cough—Epirubicin—stomach cancer	7.63e-05	0.00055	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—stomach cancer	7.63e-05	0.00055	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—stomach cancer	7.63e-05	0.00055	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—stomach cancer	7.59e-05	0.000547	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—stomach cancer	7.58e-05	0.000546	CcSEcCtD
Buprenorphine—Infection—Methotrexate—stomach cancer	7.58e-05	0.000546	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—stomach cancer	7.55e-05	0.000544	CcSEcCtD
Buprenorphine—Hypersensitivity—Capecitabine—stomach cancer	7.55e-05	0.000544	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—stomach cancer	7.51e-05	0.000541	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—stomach cancer	7.49e-05	0.00054	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—stomach cancer	7.48e-05	0.000539	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—stomach cancer	7.45e-05	0.000537	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—stomach cancer	7.45e-05	0.000537	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—stomach cancer	7.45e-05	0.000537	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—stomach cancer	7.44e-05	0.000536	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—stomach cancer	7.42e-05	0.000535	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—stomach cancer	7.41e-05	0.000534	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	7.4e-05	0.000533	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—stomach cancer	7.38e-05	0.000532	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—stomach cancer	7.36e-05	0.00053	CcSEcCtD
Buprenorphine—Asthenia—Capecitabine—stomach cancer	7.35e-05	0.00053	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—stomach cancer	7.3e-05	0.000526	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—stomach cancer	7.28e-05	0.000525	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—stomach cancer	7.27e-05	0.000524	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—stomach cancer	7.27e-05	0.000524	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—stomach cancer	7.26e-05	0.000523	CcSEcCtD
Buprenorphine—Pruritus—Capecitabine—stomach cancer	7.25e-05	0.000523	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—stomach cancer	7.24e-05	0.000522	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—stomach cancer	7.2e-05	0.000519	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—stomach cancer	7.15e-05	0.000516	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—stomach cancer	7.14e-05	0.000515	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—stomach cancer	7.14e-05	0.000515	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—stomach cancer	7.13e-05	0.000514	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—stomach cancer	7.11e-05	0.000513	CcSEcCtD
Buprenorphine—Infection—Epirubicin—stomach cancer	7.09e-05	0.000511	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—stomach cancer	7.06e-05	0.000509	CcSEcCtD
Buprenorphine—Shock—Epirubicin—stomach cancer	7.02e-05	0.000506	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—stomach cancer	7.01e-05	0.000505	CcSEcCtD
Buprenorphine—Diarrhoea—Capecitabine—stomach cancer	7.01e-05	0.000505	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—stomach cancer	7e-05	0.000505	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—stomach cancer	7e-05	0.000505	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—stomach cancer	6.99e-05	0.000504	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—stomach cancer	6.97e-05	0.000502	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—stomach cancer	6.95e-05	0.000501	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—stomach cancer	6.93e-05	0.0005	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—stomach cancer	6.9e-05	0.000497	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—stomach cancer	6.9e-05	0.000497	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—stomach cancer	6.89e-05	0.000497	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—stomach cancer	6.89e-05	0.000497	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—stomach cancer	6.89e-05	0.000497	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—stomach cancer	6.87e-05	0.000495	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—stomach cancer	6.85e-05	0.000494	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	6.84e-05	0.000493	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—stomach cancer	6.81e-05	0.000491	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—stomach cancer	6.81e-05	0.000491	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—stomach cancer	6.8e-05	0.00049	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—stomach cancer	6.78e-05	0.000489	CcSEcCtD
Buprenorphine—Dizziness—Capecitabine—stomach cancer	6.78e-05	0.000488	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—stomach cancer	6.74e-05	0.000486	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—stomach cancer	6.73e-05	0.000485	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—stomach cancer	6.72e-05	0.000484	CcSEcCtD
Buprenorphine—Rash—Docetaxel—stomach cancer	6.67e-05	0.000481	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—stomach cancer	6.67e-05	0.000481	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—stomach cancer	6.67e-05	0.000481	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—stomach cancer	6.66e-05	0.00048	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—stomach cancer	6.63e-05	0.000478	CcSEcCtD
Buprenorphine—Headache—Docetaxel—stomach cancer	6.63e-05	0.000478	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—stomach cancer	6.61e-05	0.000476	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—stomach cancer	6.61e-05	0.000476	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—stomach cancer	6.59e-05	0.000475	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—stomach cancer	6.58e-05	0.000474	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—stomach cancer	6.56e-05	0.000473	CcSEcCtD
Buprenorphine—Pain—Methotrexate—stomach cancer	6.52e-05	0.00047	CcSEcCtD
Buprenorphine—Vomiting—Capecitabine—stomach cancer	6.52e-05	0.00047	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—stomach cancer	6.5e-05	0.000469	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—stomach cancer	6.5e-05	0.000468	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—stomach cancer	6.48e-05	0.000467	CcSEcCtD
Buprenorphine—Rash—Capecitabine—stomach cancer	6.46e-05	0.000466	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—stomach cancer	6.46e-05	0.000465	CcSEcCtD
Buprenorphine—Dermatitis—Capecitabine—stomach cancer	6.46e-05	0.000465	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—stomach cancer	6.45e-05	0.000465	CcSEcCtD
Buprenorphine—Headache—Capecitabine—stomach cancer	6.42e-05	0.000463	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—stomach cancer	6.42e-05	0.000462	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—stomach cancer	6.41e-05	0.000462	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—stomach cancer	6.39e-05	0.00046	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—stomach cancer	6.36e-05	0.000459	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—stomach cancer	6.35e-05	0.000457	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—stomach cancer	6.3e-05	0.000454	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—stomach cancer	6.29e-05	0.000453	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—stomach cancer	6.29e-05	0.000453	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—stomach cancer	6.28e-05	0.000453	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—stomach cancer	6.24e-05	0.00045	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—stomach cancer	6.21e-05	0.000447	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—stomach cancer	6.17e-05	0.000445	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—stomach cancer	6.16e-05	0.000444	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—stomach cancer	6.16e-05	0.000444	CcSEcCtD
Buprenorphine—Pain—Epirubicin—stomach cancer	6.11e-05	0.00044	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—stomach cancer	6.11e-05	0.00044	CcSEcCtD
Buprenorphine—Nausea—Capecitabine—stomach cancer	6.09e-05	0.000439	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—stomach cancer	6.06e-05	0.000437	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—stomach cancer	6.03e-05	0.000435	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—stomach cancer	6.03e-05	0.000435	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	6.02e-05	0.000434	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—stomach cancer	5.97e-05	0.000431	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—stomach cancer	5.93e-05	0.000428	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—stomach cancer	5.89e-05	0.000424	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—stomach cancer	5.88e-05	0.000424	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—stomach cancer	5.87e-05	0.000423	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—stomach cancer	5.84e-05	0.000421	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—stomach cancer	5.81e-05	0.000419	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—stomach cancer	5.74e-05	0.000414	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—stomach cancer	5.7e-05	0.000411	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—stomach cancer	5.7e-05	0.000411	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—stomach cancer	5.67e-05	0.000409	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—stomach cancer	5.65e-05	0.000407	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—stomach cancer	5.65e-05	0.000407	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—stomach cancer	5.64e-05	0.000407	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—stomach cancer	5.64e-05	0.000407	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—stomach cancer	5.62e-05	0.000405	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—stomach cancer	5.47e-05	0.000395	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—stomach cancer	5.44e-05	0.000392	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—stomach cancer	5.4e-05	0.000389	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—stomach cancer	5.4e-05	0.000389	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—stomach cancer	5.26e-05	0.000379	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—stomach cancer	5.25e-05	0.000378	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—stomach cancer	5.22e-05	0.000376	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—stomach cancer	5.22e-05	0.000376	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—stomach cancer	5.22e-05	0.000376	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—stomach cancer	5.12e-05	0.000369	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—stomach cancer	5.05e-05	0.000364	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—stomach cancer	5.04e-05	0.000364	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—stomach cancer	4.88e-05	0.000352	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—stomach cancer	4.87e-05	0.000351	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—stomach cancer	4.85e-05	0.00035	CcSEcCtD
Buprenorphine—Rash—Methotrexate—stomach cancer	4.81e-05	0.000347	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—stomach cancer	4.81e-05	0.000346	CcSEcCtD
Buprenorphine—Headache—Methotrexate—stomach cancer	4.78e-05	0.000344	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—stomach cancer	4.74e-05	0.000342	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—stomach cancer	4.72e-05	0.00034	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—stomach cancer	4.67e-05	0.000337	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—stomach cancer	4.54e-05	0.000327	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—stomach cancer	4.53e-05	0.000327	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—stomach cancer	4.52e-05	0.000326	CcSEcCtD
Buprenorphine—Rash—Epirubicin—stomach cancer	4.5e-05	0.000324	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—stomach cancer	4.5e-05	0.000324	CcSEcCtD
Buprenorphine—Headache—Epirubicin—stomach cancer	4.47e-05	0.000322	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—stomach cancer	4.37e-05	0.000315	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—stomach cancer	4.24e-05	0.000306	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—stomach cancer	4.2e-05	0.000303	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—stomach cancer	4.17e-05	0.0003	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—stomach cancer	4.16e-05	0.0003	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—stomach cancer	4.14e-05	0.000298	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—stomach cancer	3.92e-05	0.000283	CcSEcCtD
Buprenorphine—CYP1A2—Metabolism—DPYD—stomach cancer	5.6e-06	7.5e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—PIK3CA—stomach cancer	5.58e-06	7.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKR1C3—stomach cancer	5.57e-06	7.46e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ALB—stomach cancer	5.55e-06	7.43e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—stomach cancer	5.47e-06	7.33e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO1—stomach cancer	5.47e-06	7.33e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PRKCB—stomach cancer	5.46e-06	7.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—FADS1—stomach cancer	5.45e-06	7.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMP—stomach cancer	5.45e-06	7.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6ST—stomach cancer	5.44e-06	7.28e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	5.43e-06	7.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO1—stomach cancer	5.43e-06	7.27e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CAV1—stomach cancer	5.41e-06	7.24e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—APOA1—stomach cancer	5.4e-06	7.23e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—PIK3CA—stomach cancer	5.38e-06	7.21e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SERPINE1—stomach cancer	5.38e-06	7.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	5.34e-06	7.15e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—stomach cancer	5.32e-06	7.13e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—NOS3—stomach cancer	5.31e-06	7.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—stomach cancer	5.29e-06	7.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CD44—stomach cancer	5.28e-06	7.07e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARG—stomach cancer	5.23e-06	7.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTM1—stomach cancer	5.23e-06	7.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—APC—stomach cancer	5.23e-06	7e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—stomach cancer	5.19e-06	6.95e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARG—stomach cancer	5.19e-06	6.95e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RHOA—stomach cancer	5.19e-06	6.95e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—stomach cancer	5.16e-06	6.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CD44—stomach cancer	5.15e-06	6.9e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOS3—stomach cancer	5.13e-06	6.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	5.12e-06	6.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SREBF2—stomach cancer	5.1e-06	6.83e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	5.07e-06	6.79e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1B—stomach cancer	5.07e-06	6.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—RORA—stomach cancer	5.04e-06	6.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPP2R1A—stomach cancer	5.03e-06	6.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK3—stomach cancer	5e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTT1—stomach cancer	4.95e-06	6.63e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—stomach cancer	4.94e-06	6.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTP1—stomach cancer	4.93e-06	6.61e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ERCC2—stomach cancer	4.92e-06	6.59e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP2A6—stomach cancer	4.89e-06	6.55e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—PIK3CA—stomach cancer	4.89e-06	6.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HMOX1—stomach cancer	4.86e-06	6.51e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD44—stomach cancer	4.85e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6R—stomach cancer	4.85e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—stomach cancer	4.85e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—stomach cancer	4.84e-06	6.48e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—JUN—stomach cancer	4.83e-06	6.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD44—stomach cancer	4.81e-06	6.45e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—stomach cancer	4.8e-06	6.43e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK1—stomach cancer	4.76e-06	6.38e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—stomach cancer	4.76e-06	6.38e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKR1C3—stomach cancer	4.76e-06	6.37e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—stomach cancer	4.75e-06	6.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALDOB—stomach cancer	4.72e-06	6.32e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—stomach cancer	4.71e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—stomach cancer	4.7e-06	6.29e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1A—stomach cancer	4.68e-06	6.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	4.67e-06	6.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—stomach cancer	4.66e-06	6.25e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO1—stomach cancer	4.64e-06	6.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—MTHFR—stomach cancer	4.62e-06	6.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—stomach cancer	4.58e-06	6.14e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK8—stomach cancer	4.57e-06	6.12e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	4.56e-06	6.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—stomach cancer	4.55e-06	6.1e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—stomach cancer	4.55e-06	6.09e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SERPINE1—stomach cancer	4.54e-06	6.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—stomach cancer	4.53e-06	6.07e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—stomach cancer	4.52e-06	6.06e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NOS3—stomach cancer	4.5e-06	6.03e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—stomach cancer	4.5e-06	6.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPP2R1A—stomach cancer	4.49e-06	6.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NOS3—stomach cancer	4.46e-06	5.98e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—stomach cancer	4.45e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—stomach cancer	4.4e-06	5.9e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX5—stomach cancer	4.39e-06	5.88e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RHOA—stomach cancer	4.38e-06	5.87e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPP2R1A—stomach cancer	4.38e-06	5.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HMOX1—stomach cancer	4.34e-06	5.81e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOS3—stomach cancer	4.34e-06	5.81e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—stomach cancer	4.33e-06	5.8e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—DPYD—stomach cancer	4.32e-06	5.78e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—stomach cancer	4.3e-06	5.75e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—stomach cancer	4.28e-06	5.73e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CAV1—stomach cancer	4.27e-06	5.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ERCC2—stomach cancer	4.26e-06	5.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOA1—stomach cancer	4.26e-06	5.7e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—stomach cancer	4.24e-06	5.68e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HMOX1—stomach cancer	4.24e-06	5.68e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—stomach cancer	4.23e-06	5.67e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—stomach cancer	4.22e-06	5.65e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—stomach cancer	4.18e-06	5.59e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—stomach cancer	4.13e-06	5.53e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPP2R1A—stomach cancer	4.13e-06	5.53e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—stomach cancer	4.12e-06	5.52e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—stomach cancer	4.12e-06	5.51e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD44—stomach cancer	4.11e-06	5.51e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—stomach cancer	4.1e-06	5.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—stomach cancer	4.09e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPP2R1A—stomach cancer	4.09e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NOS3—stomach cancer	4.09e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—stomach cancer	4.08e-06	5.47e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—stomach cancer	4.06e-06	5.43e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—stomach cancer	4.05e-06	5.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—stomach cancer	4.05e-06	5.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—stomach cancer	4.01e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—stomach cancer	4.01e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK8—stomach cancer	4e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—stomach cancer	3.99e-06	5.35e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HMOX1—stomach cancer	3.99e-06	5.35e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	3.99e-06	5.34e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—stomach cancer	3.99e-06	5.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HMOX1—stomach cancer	3.96e-06	5.3e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—stomach cancer	3.95e-06	5.29e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—stomach cancer	3.88e-06	5.2e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—stomach cancer	3.85e-06	5.15e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—stomach cancer	3.82e-06	5.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—stomach cancer	3.82e-06	5.12e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—stomach cancer	3.8e-06	5.09e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK1—stomach cancer	3.8e-06	5.08e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—stomach cancer	3.79e-06	5.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—stomach cancer	3.78e-06	5.06e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2A6—stomach cancer	3.77e-06	5.06e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—stomach cancer	3.76e-06	5.04e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—stomach cancer	3.76e-06	5.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—stomach cancer	3.75e-06	5.02e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—stomach cancer	3.74e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—stomach cancer	3.73e-06	5e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—stomach cancer	3.72e-06	4.98e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—stomach cancer	3.71e-06	4.97e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—stomach cancer	3.7e-06	4.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAV1—stomach cancer	3.69e-06	4.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—stomach cancer	3.69e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOA1—stomach cancer	3.69e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKR1C3—stomach cancer	3.67e-06	4.92e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—stomach cancer	3.66e-06	4.9e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—stomach cancer	3.66e-06	4.9e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—stomach cancer	3.58e-06	4.8e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—stomach cancer	3.58e-06	4.8e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO1—stomach cancer	3.58e-06	4.79e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—stomach cancer	3.58e-06	4.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—stomach cancer	3.57e-06	4.79e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.53e-06	4.73e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—stomach cancer	3.5e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—stomach cancer	3.5e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPP2R1A—stomach cancer	3.5e-06	4.68e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—stomach cancer	3.49e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—stomach cancer	3.48e-06	4.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—stomach cancer	3.47e-06	4.64e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—stomach cancer	3.47e-06	4.64e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—stomach cancer	3.43e-06	4.59e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—stomach cancer	3.4e-06	4.56e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK8—stomach cancer	3.38e-06	4.53e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMOX1—stomach cancer	3.38e-06	4.53e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—stomach cancer	3.37e-06	4.52e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK1—stomach cancer	3.33e-06	4.46e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—stomach cancer	3.33e-06	4.46e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAV1—stomach cancer	3.3e-06	4.42e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—stomach cancer	3.29e-06	4.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOA1—stomach cancer	3.29e-06	4.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—stomach cancer	3.29e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—stomach cancer	3.26e-06	4.37e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—stomach cancer	3.25e-06	4.35e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NOS3—stomach cancer	3.23e-06	4.32e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAV1—stomach cancer	3.22e-06	4.31e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOA1—stomach cancer	3.21e-06	4.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—stomach cancer	3.19e-06	4.27e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—stomach cancer	3.19e-06	4.27e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD44—stomach cancer	3.17e-06	4.25e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—stomach cancer	3.15e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.15e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—stomach cancer	3.14e-06	4.21e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—stomach cancer	3.13e-06	4.19e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—stomach cancer	3.09e-06	4.14e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—stomach cancer	3.05e-06	4.08e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAV1—stomach cancer	3.03e-06	4.06e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOA1—stomach cancer	3.03e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAV1—stomach cancer	3.01e-06	4.03e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOA1—stomach cancer	3e-06	4.02e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—stomach cancer	2.99e-06	4e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—stomach cancer	2.96e-06	3.97e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—stomach cancer	2.96e-06	3.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—stomach cancer	2.95e-06	3.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—stomach cancer	2.92e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—stomach cancer	2.92e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—stomach cancer	2.9e-06	3.88e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—stomach cancer	2.89e-06	3.87e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—stomach cancer	2.88e-06	3.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.87e-06	3.85e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—stomach cancer	2.83e-06	3.79e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK1—stomach cancer	2.81e-06	3.77e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—stomach cancer	2.81e-06	3.77e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—stomach cancer	2.79e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NOS3—stomach cancer	2.79e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—stomach cancer	2.79e-06	3.73e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPP2R1A—stomach cancer	2.7e-06	3.61e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—stomach cancer	2.67e-06	3.58e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—stomach cancer	2.67e-06	3.57e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—stomach cancer	2.66e-06	3.56e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—stomach cancer	2.65e-06	3.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—stomach cancer	2.64e-06	3.54e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMOX1—stomach cancer	2.61e-06	3.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—stomach cancer	2.61e-06	3.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAV1—stomach cancer	2.57e-06	3.44e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOA1—stomach cancer	2.56e-06	3.43e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—stomach cancer	2.56e-06	3.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—stomach cancer	2.55e-06	3.42e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—stomach cancer	2.54e-06	3.41e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—stomach cancer	2.53e-06	3.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—stomach cancer	2.51e-06	3.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NOS3—stomach cancer	2.49e-06	3.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—stomach cancer	2.46e-06	3.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	2.45e-06	3.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—stomach cancer	2.44e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NOS3—stomach cancer	2.43e-06	3.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—stomach cancer	2.43e-06	3.26e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—stomach cancer	2.4e-06	3.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—stomach cancer	2.38e-06	3.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—stomach cancer	2.36e-06	3.16e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—stomach cancer	2.3e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NOS3—stomach cancer	2.29e-06	3.07e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—stomach cancer	2.29e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—stomach cancer	2.28e-06	3.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NOS3—stomach cancer	2.27e-06	3.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—stomach cancer	2.26e-06	3.03e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—stomach cancer	2.26e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—stomach cancer	2.23e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—stomach cancer	2.16e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—stomach cancer	2.15e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—stomach cancer	2.1e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—stomach cancer	2.08e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—stomach cancer	2.03e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAV1—stomach cancer	1.98e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA1—stomach cancer	1.98e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NOS3—stomach cancer	1.94e-06	2.6e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—stomach cancer	1.81e-06	2.43e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—stomach cancer	1.78e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—stomach cancer	1.74e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—stomach cancer	1.57e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—stomach cancer	1.57e-06	2.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NOS3—stomach cancer	1.5e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—stomach cancer	1.4e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—stomach cancer	1.37e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—stomach cancer	1.37e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—stomach cancer	1.29e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—stomach cancer	1.28e-06	1.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—stomach cancer	1.09e-06	1.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—stomach cancer	8.44e-07	1.13e-05	CbGpPWpGaD
